Medicine
Right drug, wrong patient: here’s how we improve our targeting
When it comes to precision and personalised medicine (PPM), clinical practice in oncology takes pride in developing and administering treatments that selectively target components of tumour cells. But, PPM is a model that also takes into account the inherent variability…
How to make precision drugs that work better
Six lessons from the development of the first targeted anti-cancer therapy Tamoxifen famously started life as a failed contraceptive, developed by ICI (now Astra Zeneca), but with the fatal flaw that it increased ovulation rather than suppressing it. It’s a…
AI will help Cinderella to see herself in the mirror
Many women who undergo breast reconstruction after mastectomy end up disappointed. It is estimated that as many as 30% of women have to live with aesthetic results they are not happy with. On the other hand, some of those who…
The unique toxicities of CAR-T cell therapy
The advent of chimeric antigen receptor T cell (CAR T cell) therapy generated great excitement in the field of onco-haematology. Clinical trials have shown remarkable results in patients with relapsed/refractory B cell malignancies, and two CAR T cell products…